AVEO Pharmaceuticals (AVEO Pharmaceuticals) EBIT per Share : $-0.71 (TTM As of Sep. 2022)

View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals EBIT per Share?

AVEO Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2022 was $-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.71.

During the past 3 years, the average EBIT per Share Growth Rate was 8.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AVEO Pharmaceuticals's EBIT per Share or its related term are showing as below:

AVEO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -39.7 Med: 34.6 Max: 82.2
Current: 8.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AVEO Pharmaceuticals was 82.20% per year. The lowest was -39.70% per year. And the median was 34.60% per year.

AVEO's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.2 vs AVEO: 8.70

AVEO Pharmaceuticals's EBIT for the three months ended in Sep. 2022 was $-2.17 Mil.

AVEO Pharmaceuticals EBIT per Share Historical Data

The historical data trend for AVEO Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals EBIT per Share Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

-5.91

-0.24

0.73

-1.59

-1.51

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT per Share	Get a 7-Day Free Trial															-0.27	-0.18	-0.26	-0.21	-0.06

AVEO Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AVEO Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-49.297	/	32.661
=	-1.51

AVEO Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2022 is calculated as

	EBIT per Share		(Q: Sep. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.168	/	34.618
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.71

AVEO Pharmaceuticals (NAS:AVEO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

AVEO Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Executives

Jebediah Ledell	officer: Chief Operating Officer	C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey	director, officer: President & CEO	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso	officer: Chief Commercial Officer	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell	10 percent owner
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera	officer: Chief Financial Officer	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring	director	AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202